Ari M. Vanderwalde

8.1k total citations · 3 hit papers
130 papers, 3.5k citations indexed

About

Ari M. Vanderwalde is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ari M. Vanderwalde has authored 130 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 40 papers in Cancer Research. Recurrent topics in Ari M. Vanderwalde's work include Lung Cancer Treatments and Mutations (46 papers), Cancer Genomics and Diagnostics (35 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Ari M. Vanderwalde is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Cancer Genomics and Diagnostics (35 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Ari M. Vanderwalde collaborates with scholars based in United States, Spain and United Kingdom. Ari M. Vanderwalde's co-authors include Igor Puzanov, Zoran Gatalica, David Spetzler, Nianqing Xiao, Kevin Gorski, John L. Marshall, Anthony J. Olszanski, Antoni Ribas, F. Stephen Hodi and John M. Kirkwood and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ari M. Vanderwalde

116 papers receiving 3.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Ari M. Vanderwalde et al. profile →
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

2019 383 citations Funda Meric‐Bernstam, Herbert I. Hurwitz et al. The Lancet Oncology profile →
Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients

2018 333 citations Ari M. Vanderwalde, David Spetzler et al. Cancer Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ari M. Vanderwalde	2.6k	847	845	832	785	130	3.5k
Paul B. Robbins	1.7k 0.7×	1.0k 1.2×	798 0.9×	758 0.9×	449 0.6×	79	3.1k
Jennifer Gansert	3.7k 1.5×	876 1.0×	911 1.1×	1.2k 1.4×	876 1.1×	31	4.5k
John C. Krauss	1.3k 0.5×	839 1.0×	852 1.0×	406 0.5×	421 0.5×	137	3.0k
Anthony S. Stein	2.9k 1.1×	1.5k 1.8×	1.2k 1.4×	354 0.4×	312 0.4×	242	6.8k
Leslie Popplewell	2.8k 1.1×	1.1k 1.3×	1.1k 1.3×	558 0.7×	357 0.5×	202	5.0k
Panagiota Economopoulou	1.4k 0.5×	891 1.1×	392 0.5×	597 0.7×	142 0.2×	105	2.7k
Diego Chowell	2.2k 0.8×	877 1.0×	1.4k 1.7×	790 0.9×	102 0.1×	37	3.3k
Marka R. Crittenden	2.8k 1.1×	719 0.8×	2.4k 2.8×	583 0.7×	212 0.3×	106	4.0k
Colin J.R. Stewart	1.9k 0.7×	1.7k 2.0×	525 0.6×	1.3k 1.5×	720 0.9×	208	6.7k
Rochelle L. Garcia	2.0k 0.8×	1.9k 2.2×	556 0.7×	528 0.6×	1.6k 2.0×	83	5.5k

Countries citing papers authored by Ari M. Vanderwalde

Since Specialization

Citations

This map shows the geographic impact of Ari M. Vanderwalde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ari M. Vanderwalde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ari M. Vanderwalde more than expected).

Fields of papers citing papers by Ari M. Vanderwalde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ari M. Vanderwalde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ari M. Vanderwalde. The network helps show where Ari M. Vanderwalde may publish in the future.

Co-authorship network of co-authors of Ari M. Vanderwalde

This figure shows the co-authorship network connecting the top 25 collaborators of Ari M. Vanderwalde. A scholar is included among the top collaborators of Ari M. Vanderwalde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ari M. Vanderwalde. Ari M. Vanderwalde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ribeiro, Jennifer R., Todd Maney, Stephanie Rock, et al.. (2025). GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling. Cancer Research Communications. 5(9). 1477–1489. 1 indexed citations

Sen, Utsav, Charles Coleman, Nishant Gandhi, et al.. (2025). SCD1 Inhibition Blocks the AKT–NRF2–SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma. Cancer Research. 85(13). 2485–2503. 11 indexed citations

Reuss, Joshua E., Nishant Gandhi, Phillip Walker, et al.. (2025). Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking. Lung Cancer. 200. 108101–108101. 1 indexed citations

Adeyelu, Tolulope, Andrew Elliott, Farah Abdulla, et al.. (2024). Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma. npj Precision Oncology. 8(1). 187–187. 7 indexed citations

Elliott, Andrew, Wendy Cozen, Evanthia T. Roussos Torres, et al.. (2024). Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8526–8526. 1 indexed citations

Elliott, Andrew, Stephen V. Liu, C. Patrick, et al.. (2024). A pan-tumor description of the genomic, transcriptomic, and immunological landscape of sodium-glucose cotransporter-2 (SGLT2) and association with clinical outcomes.. Journal of Clinical Oncology. 42(23_suppl). 104–104. 1 indexed citations

Elliott, Andrew, Yasmine Baca, Mark E. Reeves, et al.. (2024). Unlocking therapeutic potential: IL-1β as a target in non-small cell lung cancer with oncogenic mutations—Prognostic and predictive insights.. Journal of Clinical Oncology. 42(16_suppl). 8030–8030. 1 indexed citations

Trabolsi, Asaad, Estelamari Rodríguez, Jennifer R. Ribeiro, et al.. (2024). Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. The Oncologist. 29(11). e1480–e1491. 7 indexed citations

Elliott, Andrew, Stephen V. Liu, C. Patrick, et al.. (2024). Abstract 5201: Characterization of PDLIM2 in non-small cell lung cancer. Cancer Research. 84(6_Supplement). 5201–5201. 1 indexed citations

10.

Watson, Alexander, Andrew Elliott, Alex Farrell, et al.. (2024). Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer. Clinical Lung Cancer. 25(8). 712–722.e1.

11.

Reuss, Joshua E., Nishant Gandhi, Phillip Walker, et al.. (2023). Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 9069–9069.

12.

Nagasaka, Misako, Shannon Zhang, Yasmine Baca, et al.. (2023). Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing. BMC Cancer. 23(1). 1000–1000. 7 indexed citations

13.

Reuss, Joshua E., Nishant Gandhi, Phillip Walker, et al.. (2023). 1399P Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer. Annals of Oncology. 34. S800–S801. 1 indexed citations

14.

Baca, Yasmine, Joanne Xiu, Fábio Távora, et al.. (2020). The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer. Molecular Cancer Therapeutics. 20(1). 183–190. 12 indexed citations

15.

Vanderwalde, Ari M., Axel Grothey, Daniel A. Vaena, et al.. (2020). Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. Journal of Personalized Medicine. 10(4). 252–252. 16 indexed citations

16.

Jonna, Sushma, Rebecca Feldman, Jeffrey Swensen, et al.. (2019). Detection of NRG1 Gene Fusions in Solid Tumors. Clinical Cancer Research. 25(16). 4966–4972. 155 indexed citations

17.

Middleton, Mark R., Joseph J. Sacco, Jaime R. Merchan, et al.. (2019). Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors. Journal for ImmunoTherapy of Cancer. 7. 1 indexed citations

18.

Meric‐Bernstam, Funda, Herbert I. Hurwitz, Kanwal Raghav, et al.. (2019). Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology. 20(4). 518–530. 383 indexed citations breakdown →

19.

Vanderwalde, Ari M., David Spetzler, Nianqing Xiao, Zoran Gatalica, & John L. Marshall. (2018). Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients. Cancer Medicine. 7(3). 746–756. 333 indexed citations breakdown →

20.

Hahn, Andrew W., et al.. (2015). Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis. Journal of the National Comprehensive Cancer Network. 13(10). 1181–1185. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact